James D. Brierley

James D. Brierley

Auto-generated profile, based on publicly available information

James D. Brierley

Princess Margaret Cancer Centre, University of Toronto

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2016
Verified
Book Chapter
Open access
MAMahul B. Amin
Mahul B. Amin
SEStephen B. Edge
Stephen B. Edge
FGFrederick L. Greene
Frederick L. Greene
DBDavid R. Byrd
David R. Byrd
RBRobert K. Brookland
Robert K. Brookland
LVLaura Meyer Vega
Laura Meyer Vega


6 August 2019 in Nature Reviews Clinical Oncology
Verified
Journal Article
Open access
PDF file
JBJames Brierley
James Brierley
BOBrian O’sullivan
Brian O’sullivan
HAHisao Asamura
Hisao Asamura
DBDavid Byrd
David Byrd
SHShao Hui Huang
Shao Hui Huang
MGMary Gospodarowicz
Mary Gospodarowicz
Disease burden is the most important determinant of survival in patients with cancer. This domain, reflected by the cancer stage and codified using the tumour-node-metastasis (TNM) classification, is a fundamental determinant of prognosis. Accurate and consistent tumour classification is required for the development and use of treatment guidelines and to enable clinical research (including clinical trials), cancer surveillance and control. Furthermore, knowledge of the extent and stage of disease is frequently important in the context of translational studies. Attempts to include additional prognostic factors in staging classifications, in order to facilitate a more accurate determination of prognosis, are often made with a lack of knowledge and understanding and are one of the main causes of the inconsistent use of terms and definitions. This effect has resulted in uncertainty and confusion, thus limiting the utility of the TNM classification. In this Position paper, we provide a consensus on the optimal use and terminology for cancer staging that emerged from a consultation process involving representatives of several major international organizations involved in cancer classification. The consultation involved several steps: a focused literature review; a stakeholder survey; and a consultation meeting. This aim of this Position paper is to provide a consensus that should guide the use of staging terminology and secure the classification of anatomical disease extent as a distinct aspect of cancer classification.

3 October 2006 in Cancer
Verified
Journal Article
Closed access
PDF file
YWYongjin Wang
Yongjin Wang
RTRichard Tsang
Richard Tsang
Sylvia L. AsaSylvia L. Asa
Sylvia L. Asa
BDBrendan Dickson
Brendan Dickson
TATamara Arenovich
Tamara Arenovich
JBJames Brierley
James Brierley

24 November 2016 in ecancermedicalscience
Verified
Journal Article
Open access
JBJames Brierley
James Brierley
MGMary Gospodarowicz
Mary Gospodarowicz
BOBrian O'SUlivan
Brian O'SUlivan
The anatomic disease extent or tumour stage of a cancer at diagnosis as a determinant of prognosis is discussed. The importance of cancer stage in individual patient prognosis and determination of treatment is reviewed as well as its value in research and cancer control activities. The conflict between the need for stability of cancer stage definitions over time and the need to evolve with advances in medicine are examined. The ecancer elearning modules on Cancer Stage are introduced.

26 October 2016
Verified
Book Chapter
Open access
DGDonna M. Gress
Donna M. Gress
SEStephen B. Edge
Stephen B. Edge
FGFrederick L. Greene
Frederick L. Greene
MWMary Kay Washington
Mary Kay Washington
EAElliot A. Asare
Elliot A. Asare
JGJeffrey E. Gershenwald
Jeffrey E. Gershenwald